Journal Articles & Book Chapters
1. Balthasar J and Fung HL, Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug. J Pharm Exp Ther 268(2): 734-9, 1994.
2. Balthasar JP and Fung HL, High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. Journal of Pharmaceutical Sciences 84(1): 2-6, 1995.
3. Balthasar JP and Fung HL, Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Life Sciences 58(7): 535-543, 1996.
4. Balthasar JP Fung HL, Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J Pharm Sci 85(10): 1035-43, 1996.
5. Bauer JA, Balthasar JP and Fung H-L, Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharm Res 14(9): 1140-45, 1997.
6. Hansen RJ and Balthasar JP, An ELISA for quantification of murine IgG in rat plasma: application to the pharmacokinetic characterization of AP-3, a murine anti-glycoprotein IIIa monoclonal antibody, in the rat. Journal of Pharmaceutical and Biomedical Analysis 21: 1011-1016, 1999.
7. Lobo ED and Balthasar JP, Highly sensitive high performance liquid chromatographic assay for methotrexate in the presence and absence of anti-methotrexate antibody fragments in rat mouse and plasma. Journal of Chromatography, B. 736: 191-199, 1999.
8. Balthasar JP, Vinorelbine tartrate and heparin sodium incompatibility. American Journal of Heath-System Pharmacy 56(Sept 15): 1891, 1999.
9. Balthasar JP, Bioequivalence and bioequivalency testing. American Journal of Pharmaceutical Education 63(2): 194-198, 1999.
10. Hansen RJ and Balthasar JP, Pharmacokinetics, pharmacodynamics, and platelet binding of 7E3, a murine anti-glycoprotein IIb/IIIa monoclonal antibody in the rat. Journal of Pharmacology and Experimental Therapeutics 298(1): 165-171, 2001.
11. Hansen RJ and Balthasar JP, Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100(6): 2087-2093, 2002.
12. Hansen RJ and Balthasar JP, Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thrombosis and Haemostasis 88(6): 898-899, 2002.
13. Lobo ED and Balthasar JP, Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit-compartment model to characterize methotrexate effects in vitro. AAPS PharmSci , article 42 http://www.aapspharmsci.org/scientific journals/pharmsci/journal/ps040442.htm, 2002.
14. Hansen RJ and Balthasar JP, IVIG effects on antiplatelet antibody levels and on platelet opsonization in ITP. Blood 101(4): 1659, 2003.
15. Hansen RJ and Balthasar JP, PK/PD modeling of the effects of intravenous immunoglobulin on the disposition of anti-platelet antibodies in a rat model of immune thrombocytopenia. Journal of Pharmaceutical Sciences, 92(6): 1206-1215, 2003.
16. Lobo ED and Balthasar JP, Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. Journal of Pharmaceutical Sciences , 92(8): 1654-1664, 2003.
17. Lobo ED, Soda DM and Balthasar JP, Application of pharmacokinetic - pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. Journal of Pharmaceutical Sciences , 92(8): 1665-1676, 2003.
18. Wang EQ, Balthasar JP and Fung HL, Pharmacodynamic modeling of in vivo nitroglycerin (NTG) tolerance in conscious rats: Effects of dose and dosage regimen. Pharmaceutical Research, 21(1): 114-120, 2004.
19. Hansen RJ and Balthasar JP, Mechanisms of IVIG action in ITP, Clinical Laboratory, 50(3/4): 133-140, 2004.
20. Lobo ED, Hansen RJ, Balthasar JP, Antibody pharmacokinetics and pharmacodynamics. Journal of Pharmaceutical Sciences, 93(11): 2645-2668), 2004.
21. Hansen RJ and Balthasar JP, IVIG effects on autoantibody elimination, Allergy, 59(10): 1124, 2004.
22. Tayab ZR and Balthasar JP, Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. Journal of Immunoassay and Immunochemistry, 25(4): 333-324, 2004.
23. Chen J and Balthasar JP, High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. J Chrom B Analyt Technol Biomed Life Sci, 816(1-2): 183-192, 2005.
24. Getman K and Balthasar JP, Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: Implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci, 94(4): 718-729, 2005.
25. Lobo ED and Balthasar JP, Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. J Pharm Sci 94:1957-64,2005.
26. Emregul E, David A, Balthasar JP and Yang VC, A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studies. J Biomed Mater Res A 75(3): 648-55, 2005.
27. Deng R and Balthasar JP, Investigation of antibody-coated liposomes as a new treatment for immune thrombocytopenia. Int J Pharm 304(1-2): 51-62, 2005.
28. Wang T, Yang Z, Emregul E, David A, Balthasar JP, Liang J and Yang VC, Strategies for improving the functionality of an affinity bioreactor. Int J Pharm, 2005.
29. Jin F and Balthasar JP, Mechanisms of intravenous immunoglobulin in immune thrombocytopenic purpura. Human Immunology, 66: 403-410, 2005.
30. Jin F, Tayab ZR and Balthasar JP, Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. AAPS J. 2006 Jan 13;7(4):E895-902.
31. Deng R and Balthasar JP, Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharm Sci, 96(6):1625-1637, 2007.
32. Deng R. and Balthasar JP, Comparison of the effects of antibody-coated liposomes, IVIG and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood, 109(6):2470-2476, 2007.
33. Shin BS, Choi JW, Balthasar JP, Hong DK, Kim JJ, Yoo SD, Determination of roxatidine in human plasma by liquid chromatography/electrospray mass spectromety and application to a clinical pharmacokinetic study, Rapid Commun Mass Spectrom., 21(3):329-35, 2007.
34. Chen J and Balthasar JP, Development and characterization of high-affinity anti-topotecan IgG and fab fragments. Chapter 6.5 in Handbook of Pharmaceutical Biotechnology, John Wiley & Sons, 2007, in press.
35. Chen J, Shin BS, and Balthasar JP, Enhancement of chemotherapeutic selectivity via active immunization. Nature Biotechnology, 2007, submitted.
37. Chen J, Lu Q, and Balthasar JP, Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. Journal of Pharmacokinetics and Pharmacodynamics, 2007, submitted.
40. Garg A and Balthasar JP, Application of a physiologically-based pharmacokinetic model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinetics and Pharmacodynamics, in press, 2007.
41. Shin BS, Shah D, and Balthasar JP, Pharmacodynamics. Chapter in Preclinical Development Handbook, John Wiley & Sons, 2007, submitted
42. Zhang W and Balthasar JP, Development and clinical applications of diabodies. Trends in biotechnology, INVITED REVIEW, in preparation.
43. Garg A and Balthasar JP, PBPK analysis of the effects of competitive inhibition of FcRn on the tissue disposition of 7E3, a monoclonal IgG1 antibody. Drug Metabolism and Disposition, submitted, 2007
44. Garg A and Balthasar JP, The neonatal Fc-receptor (FcRn) does not contribute to the blood-brain barrier for IgG antibodies. Pharm Res, submitted, 2007.